The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.

Decibel Therapeutics, a US-based hearing loss drug developer backed by corporates Alphabet, GlaxoSmithKline (GSK) and Regeneron, priced its shares at $18 to raise more than $127m in its IPO on the Nasdaq Global Select Market on Thursday. The company issued slightly more than 7 million shares and beat its original target of $75m. Shares briefly…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.